This occurs in addition to a hypertrophic effect, implying that local CRFR2 agonism may be a useful therapeutic approach in the treatment of IR syndromes including T2D and sarcopaenic obesity. This evidence concerns the gene CRHR2 and type 2 diabetes mellitus.